Representative David Taylor (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 3rd. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.
Representative David Taylor also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/5/2026.
- Sold $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 11/5/2026.
- Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/5/2026.
- Purchased $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 11/5/2026.
- Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 11/3/2026.
- Sold $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 11/3/2026.
- Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 11/3/2026.
- Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/3/2026.
- Sold $1,001 – $15,000 in shares of Visa (NYSE:V) on 11/3/2026.
- Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 11/3/2026.
Eli Lilly and Company Stock Performance
NYSE:LLY traded up $16.77 during mid-day trading on Friday, hitting $1,444.05. The company’s stock had a trading volume of 2,080,606 shares, compared to its average volume of 3,003,279. The business’s fifty day moving average is $1,242.25 and its two-hundred day moving average is $1,110.30. The stock has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.71 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $850.51 and a 1 year high of $1,460.00.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on LLY. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a report on Monday, November 9th. China Merchants Securities cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday. Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, October 30th. Truist Financial reiterated a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.
Check Out Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company News Summary
These are some of the LLY news items that stood out recently:
- Positive Sentiment: China approved Lilly’s oral weight-loss drug orforglipron, marketed as Foundayo. As the first GLP-1 weight-loss pill approved in China, it gives Lilly an early foothold in a large market and could broaden access beyond injectable treatments; competition from other drugmakers remains a factor. Reuters: China approves Eli Lilly’s weight loss pill orforglipron
- Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
- Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
Hedge Funds Weigh In On Eli Lilly and Company
Hedge funds have recently bought and sold shares of the business. Torren Management LLC increased its holdings in Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after acquiring an additional 25 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. raised its position in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the period. Foresight Capital Management Advisors Inc. purchased a new position in Eli Lilly and Company during the third quarter valued at $49,000. AlphaCentric Advisors LLC purchased a new position in Eli Lilly and Company during the first quarter valued at $42,000. Finally, Sumitomo Mitsui Financial Group Inc. lifted its holdings in Eli Lilly and Company by 5,100.0% during the third quarter. Sumitomo Mitsui Financial Group Inc. now owns 52 shares of the company’s stock valued at $60,000 after purchasing an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Insider Activity
In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.
About Representative Taylor
David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.
David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
